Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2005-12-27
2005-12-27
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S660000
Reexamination Certificate
active
06979698
ABSTRACT:
The treatment of learning, memory, and age-related memory disorders includes administration of a nicotine antagonist. The preferred nicotine antagonists are mecamylamine, a mecamylamine analog, or a mecamylamine stereoisomer. The effective amount of the nicotine antagonist is 0.005–1.00 mg/kg/day. Alternatively, the method utilizes a partial nicotine agonist.
REFERENCES:
patent: 2831027 (1958-04-01), Pfister, III et al.
patent: 2894987 (1959-07-01), Gustav et al.
patent: 3148118 (1964-09-01), Thesing et al.
patent: 3164601 (1965-01-01), Thesing et al.
patent: 4837218 (1989-06-01), Olney
patent: 4891380 (1990-01-01), Williams et al.
patent: 5204470 (1993-04-01), Cliffe
patent: 5554610 (1996-09-01), Williams et al.
patent: 5574052 (1996-11-01), Rose et al.
patent: 5583140 (1996-12-01), Bencherif et al.
patent: 5691365 (1997-11-01), Crooks et al.
patent: 5859004 (1999-01-01), Olesen
patent: 6734215 (2004-05-01), Shytle et al.
patent: 0 537 993 (1993-04-01), None
Suzuki et al. “Mecamylamine-precipitated nicotine-withdrawal aversion in rats.” European Journal of Pharmacology, 1996, vol. 314, No. 3, pp. 281-284.
Hayashi, E., et al., “Comparative studies on anti-nicotinic action of hexamethonium, mecamylamine and adenosine in the guinea pig isolated ileum,”Japan J. Pharmacol, 27: 659-665 (1997).
Sanberg, P.R., et al., “Nicotine for the Treatment of Tourette's Syndrome,”Pharmacol. Ther. 74(1): 21-25 (1997).
Suchocki, J.A., et al., “Synthesis of 2-exo-and 2-end-mecamylamine analogs. Structure-activity relationships for nicotinic antagonism in the central nervous system,”Journal of Medicinal Chemistry, 34: 1003-1010 (1991).
European Patent Application No. 98 93 9328.5, Supplementary European Search Report issued Dec. 3, 2003.
Ballivet, et al., “Nicotine Acetylcholine . . . elegans,” JMB., 2296, pp. 261-269 (1996).
Banerjee, et al., “[3H]Mecamylamine Binding to Rat Brain Membranes,”Biochemical Pharmacology, vol. 40, No. 9, pp. 2105-2110 (1990).
Bianchi, C. and L. Tomasi, “Central nervous system and autonomic nervous system effects of amantadine and of some standard anti-Parkinson drugs,”Pharmacology, 10(4):226-237 (1973).
Bruun, R.D. and C.L. Budman, “Risperidone as a treatment for Tourette's syndrome,”J.Clin. Psychiatry, 57(1):29-31 (1996).
Emerich, et al., “Nicotine . . . Locomotor Hypoactivity,”Pharm. Biochem.&Behav., vol. 38, pp. 875-880 (1991).
Emerich, et al., Nicotine . . . of Haloperidol, Psychopharm. Bulletin., vol. 27(3): 385-390 (1991).
Erdmann, R., “Nicotine in neuropsychiatric movement disorders,”Fortschr Neurol Psychiatr., 64(9): 362-366 (1996).
Freund, R.K., et al., “Nicotine effects in mouse hippocampus are blocked by mecamylamine, but not other nicotinic antagonists,”Brain Res., 511(2): 187-191 (1990).
Ghaemi, S.N., et al., “Acute treatment of bipolar disorder with adjunctive risperidone in outpatients,”Can. J. Psychiatry, 42(2): 196-199 (1997).
Green, M.F., et al., “Does Risperidone Improve Verbal Working Memory in Treatment-Resistant Schizophrenia?”American Journal of Psychiatry, 154(6): 799-804 (1997).
Hsu, W., “Toxicity and Drug Interactions of Levamisole,”HAVMA, vol. 176, No. 10, pp. 1166-1169 (May 1980).
Ivanová, S. and A. J. Greenshaw, “Nicotine-induced decreases in VTA electrical self-stimulation thresholds: blockade by haloperidol and mecamylamine but not scopolaminc or ondansetron,”Psychopharmacology, 134(2): 187-192 (1997).
Jankovic, J. and H. Rohaidy, “Motor, behavior and pharmacologic findings in Tourette's Syndrome,”Can. J. Neurol. Sci.,14(3 Suppl.): 541-546 (1987).
Jolles, J., et al., “Cognitive Impairment in Elderly People,”Drugs&Aging, 7(6): 459-479 (1995).
The Lancet, “Nicotine Gum & Haloperidol in Tourette's Syndrome,” p. 592 (Mar. 12, 1998).
The Lancet, “Transdermal nicotine patch . . . in Tourette's Syndrome,” vol. 342, p. 182 (Jul. 17, 1993).
Levin, E. D. and D. Torry, “Acute and chronic nicotine effects on working memory in aged rats,”Psychopharmacology, 123: 88-97 (1996).
Lindström, E., et al., “Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia,”Clin. Ther.17(3): 402-412 (1995).
Lombroso, P.J., et al., “Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report,”J. Am. Acad. Child Adolesc. Psychiatry, 34(9): 1147-1152 (1995).
Lomboros, P.J., et al., “Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report,”J. Am. Acad. Child Adolsec. Psychiatry, 35 (3): 394 (1966).
McConville, et al., “The Effects . . . in Tourette's Disorder,”Biol. Psychiatry, vol. 31 (8): 832-840 (1992).
McConville, et al., “Nicontine . . . in Tourette's Syndrome,”Amer. J. Psychiatry, 148(6): 793-794 (Jun. 1991).
Pharmacol Ther., “Nicotine for the Treatment of Tourette's Syndrome,” vol. 74, No. 1, pp. 21-25 (1997).
Psychopharmacologia(Berl.) “Nicotine-Like . . . after . . . Mecamylamine in . . . rats,” 46, pp. 119-121 (1976).
Rupniak, et al., “Antinociceptive and Toxic Effect . . . Attributable to Nicotinic Agonist Activity,”Brit. J. Pharmacol., 113(4): 1487-1493 (1994).
Sallee, F.R., et al., “Effects of pimozide on cognition in children with Tourette syndrome: interaction with comorbid attention deficit hyperactivity disorder,”Acta.l Psychiatr. Scand., 90(1): 4-9 (1994).
Sallee, F.R.., et al., “Pharmacokinetics of pimozide in adults and children with Tourette's syndrome,”J. Clin. Pharacol.,27(10): 776-781 (1987).
Sallee, F.R., et al., “Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder,”Am. J. Psychiatry, 154(8): 1057-1062 (1997).
Sanberg, et al., “Nicotine as a Therapeutic Adjunct for Tourette's Syndrome,” pp. 35-41 (1997).
Sanberg, et al., “Nicotine . . . with Tourette's Syndrome,”Biomed&Pharmacother., 43, pp. 19-23 (1989).
Sanberg, et al., “Nicontine . . . Striatal Mechanisms,”Pharmacol. Biochem&Behavior, vol. 46: 303-307 (1993).
Sano Corporation website (1997).
Sawada, S., et al., “Augmenting action of nicotine on population spikes in the dentate gyrus of the guinea pig,”Neurosci Res., 20(4):317-322 (1994).
Schonenberger, et al., “Preparation of Optically Active . . . ,”Helvetica Chimica Acta, vol. 69, pp. 283-287 (1986).
Seumaru, et al., “Characteristics of tail-tremor induced by nivotine in rats,”Naonyn-Schmledeberg's Arch Pharmacol, 350:153-157 (1994).
Shapiro, E., et al., “Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome,”Arch. Gen. Psychiatry, 46(8): 722-730 (1989).
Shieh, et al., “Sexual Differences in the Diurnal Changes . . . of Neuron Activity in Rat: Role of Cholinergic Control,”Biology of Reproduction, vol. 54, pp. 987-992 (1996).
Shytle et al., “Nicotine, Tobacco and Addiction,”Int'l Weekly Journal of Science, vol. 384, pp. 18-19 (1997).
Shytle, et al., “Researchers Exploring . . . TS Treatment,”Tourette Syn. Assoc., 25(1): 1, 3, 7 (1997).
Shytle, et al., “Transdermal Nicotine for Tourette's Syndrome,”Drug Development Research, vol. 38, pp. 290-298 (1996).
Silver, et al., “Case Study . . . In Tourette's Syndrome,”J. Amer. Child&Adolesc. Psych., vol. 35(12), pp. 1631-1636 (1996).
Stone, et al., “Chemistry and Structure-Activity Relationship of Mecamylamine and Derivatives,”Journal of Medicine&Pharm. Chemistry, vol., 5(4), pp. 665-690 (1962).
The Merk Index, “5654. Mecamylamine,” p. 905 (1989).
Sandberg Paul R.
Shytle Roland D.
Silver Archie A.
Kim Jennifer
Padmanabhan Sreeni
Targacept, Inc.
Womble Carlyle Sandridge & Rice PLLC
LandOfFree
Method of treating cognitive deficits in learning and memory does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating cognitive deficits in learning and memory, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating cognitive deficits in learning and memory will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3508320